We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
High-signal headlines only — macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) ranks among the most profitable biotech stocks to buy now. On April 13, TD Cowen reaffirmed its Buy rating and $96 price target for Halozyme Therapeutics, Inc. (NASDAQ:HALO). The firm forecasts Halozyme to continue to outperform expectations and enhance guidance due to strong growth catalysts such as Vyvgart Hytrulo, Darzalex Faspro, […]
Halozyme Therapeutics has seen its modelled Fair Value price target updated to $85.78 from $84.89, reflecting a modest recalibration in the latest assumptions. Analysts linking this change to current research point to royalty streams, ENHANZE collaborations, and acquired subcutaneous platforms as key factors shaping views on valuation and execution risk. As you read on, you will see how these moving pieces feed into the evolving narrative around Halozyme and what to watch next in the...
Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the most undervalued biotech stocks to buy right now. Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced on April 7 that its wholly-owned subsidiary, Halozyme Hypercon, Inc., entered into a global exclusive collaboration and license agreement with Vertex Pharmaceuticals Incorporated. According to the collaboration, Vertex has licensed Halozyme Therapeutics’ (NASDAQ:HALO) Hypercon™ technology […]
Travere (TVTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.